Laboratorios Litaphar is Pharmaceuticals in Spain that focus on progesterone receptor antagonists business. Founded in 2001. They cover business area such as developer, distributor, genetic and therapeutic pharmaceutical product, therapeutic product, illness, woman, cure, disease, gynecology, obstetric, prostaglandin analogue, progesterone receptor antagonist, selective modulator, their sexuality, vulvar health.
2001
( 23 years old in 2024 )
Progesterone Receptor Antagonists
-
Loiolabide, 7
20730 Azpeitia
Spain
Private
developerdistributorgenetic and therapeutic pharmaceutical producttherapeutic productillnesswomancurediseasegynecologyobstetricprostaglandin analogueprogesterone receptor antagonistselective modulatortheir sexualityvulvar health
* We use standard office opening hours in near Laboratorios Litaphar's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Laboratorios Litaphar is Pharmaceuticals business from Spain that founded in 2001 (23 years old in 2024), Laboratorios Litaphar business is focusing on Progesterone Receptor Antagonists.
Laboratorios Litaphar headquarter office and corporate office address is located in Loiolabide, 7 20730 Azpeitia Spain.
Laboratorios Litaphar was founded in Spain.
In 2024, Laboratorios Litaphar is currently focus on progesterone receptor antagonists sector.
Above is snippet of Google Trends for "progesterone receptor antagonists" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Laboratorios Litaphar, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
